Fed Circuit refuses to revive Biogen’s MS drug dispute

22-12-2020

Fed Circuit refuses to revive Biogen’s MS drug dispute

PictureDesignSwiss / Shutterstock.com

Biogen has lost its long-standing fight to recover billions of dollars in royalties from the sale of a multiple sclerosis (MS) drug, after the US Court of Appeals for the Federal Circuit rejected Biogen’s request that it reconsider its own ruling on Friday, December 18.


US Court of Appeals for the Federal Circuit, biotechnology, multiple sclerosis, Rebif, Avonex, Biogen, EMD Serono, Pfizer, Merck KGaA, patent infringement,

LSIPR